title: Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma.
abstract: OBJECTIVE
  To determine the safety and usefulness of a novel anticancer drug, miriplatin, in transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma.
  
  
  METHODS
  Patients (n=115) who underwent TACE with miriplatin-lipiodol suspension (miriplatin group), and control patients (n=131) who underwent TACE with cisplatin-lipiodol suspension (CDDP group) took part in this study.
  
  
  RESULTS
  The overall incidence of adverse events was significantly lower in the miriplatin group. The percentage of patients attaining treatment effect 4 in both groups was not significantly different. The proportion exhibiting a >50% decrease in positive tumor markers following TACE was significantly greater in the CDDP group for alpha-fetoprotein, but not significantly different for des-gammma-carboxy prothrombin.
  
  
  CONCLUSIONS
  Miriplatin-lipiodol suspension was associated with reduced intensity of adverse events and had comparable short-term therapeutic effects to cisplatin-lipiodol suspension, thereby indicating its usefulness in TACE.
authors.affiliation: Department of Surgery, NTT West Kyusyu Hospital, Shinyashiki 1-17-27, Kumamoto 862-8655, Japan. okabe-km@s8.kcn-tv.ne.jp
authors.forename: Kazutoshi
authors.initials: K
authors.lastname: Okabe
authors.forename: Toru
authors.initials: T
authors.lastname: Beppu
authors.forename: Katsuki
authors.initials: K
authors.lastname: Haraoka
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Oh-Uchida
authors.forename: Sadahiro
authors.initials: S
authors.lastname: Yamamura
authors.forename: Shinjiro
authors.initials: S
authors.lastname: Tomiyasu
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Yamanaka
authors.forename: Osamu
authors.initials: O
authors.lastname: Sano
authors.forename: Toshiro
authors.initials: T
authors.lastname: Masuda
authors.forename: Akira
authors.initials: A
authors.lastname: Chikamoto
authors.forename: Shigetoshi
authors.initials: S
authors.lastname: Fujiyama
authors.forename: Hideo
authors.initials: H
authors.lastname: Baba
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D016461:Chemoembolization, Therapeutic; D004998:Ethiodized Oil / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C406530:miriplatin; D004998:Ethiodized Oil